Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A Hidden Driver Mutation in Myeloproliferative Neoplasms: SH2B3 and Diagnostic Implications and Response to Ropeginterferon Alfa-2b.

Journal of investigative medicine high impact case reports - 1 Jan 2026

Basmajian Karina, Chang Borecky Lauren Rachel, Akhtari Mojtaba

Abstract excerpt

Myeloproliferative neoplasms (MPNs) are commonly linked to driver mutations in the JAK2, MPL, and CALR genes. In contrast, SH2B3 (LNK) mutations are uncommon and remain an under-characterized contributor to dysregulated JAK-STAT signaling. The clinical features and treatment responsiveness of SH2B3-mutated MPNs are not well defined, and data on outcomes with ropeginterferon alfa-2b in this molecular subgroup are...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to CALR gene

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Interferon-alpha

Share to Interferon alpha-2

Share to Mutation

Share to Myeloproliferative Disorders

Share to Polyethylene Glycols

Share to Recombinant Proteins

Source

Open in PubMed Open full text

Identifiers

PMID: 42351351
DOI: 10.1177/23247096261462335
PMCID: PMC13305519

Genes

SH2B3
CALR
JAK2
MPL

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A Hidden Driver Mutation in Myeloproliferative Neoplasms: SH2B3 and Diagnostic Implications and Response to Ropeginterferon Alfa-2b.PMID 42351351Read ↗

Myeloproliferative Neoplasms: Molecular Drivers and Therapeutics.Semantic proximity Read ↗

Exploring the Molecular Landscape of Myelofibrosis, with a Focus on Ras and Mitogen-Activated Protein (MAP) Kinase SignalingSemantic proximity Read ↗

Pathogenesis of myeloproliferative neoplasms.Semantic proximity Read ↗

Understanding triple negative myeloproliferative neoplasms: pathogenesis, clinical features, and management.Semantic proximity Read ↗

How does JAK2V617F contribute to the pathogenesis of myeloproliferative neoplasms?Semantic proximity Read ↗

JAK2 inhibitors in the treatment of myeloproliferative neoplasms.Semantic proximity Read ↗

[BCR::ABL-Negative Triple Negative Myeloproliferative Neoplasm --Review].Semantic proximity Read ↗

Triple-Negative Myelofibrosis: Disease Features, Response to Treatment and Outcomes.Semantic proximity Read ↗

Lymphoid blast transformation in an MPN with BCR-JAK2 treated with ruxolitinib: putative mechanisms of resistanceSemantic proximity Read ↗

JAK2 in Myeloproliferative Neoplasms: Still a ProtagonistSemantic proximity Read ↗

Mutations in MPNs: prognostic implications, window to biology, and impact on treatment decisionsSemantic proximity Read ↗

Molecular pathways: Jak/STAT pathway: mutations, inhibitors, and resistance.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.